Back to top
more

BioScrip, Inc. (BIOS)

(Delayed Data from NSDQ)

$1.98 USD

1.98
1,268,889

+0.05 (2.59%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.98 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is BioScrip (BIOS) Up 18.7% Since Last Earnings Report?

by Zacks Equity Research

BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BioScrip (BIOS) Q3 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

A shift in BioScrip's (BIOS) strategy to focus on growing its core revenue mix plus contract changes with the UnitedHealthcare dent the company's revenue rise in Q3.

BioScrip (BIOS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioScrip (BIOS) delivered earnings and revenue surprises of -28.57% and 5.79%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

BioScrip (BIOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

BioScrip (BIOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioScrip Grows on CORE Plan, Reimbursement Issues Persist

by Zacks Equity Research

BioScrip (BIOS) progresses well on the back of its new multi-faceted CORE plan to improve its financial position.

BioScrip (BIOS) Up 4.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Top

    by Zacks Equity Research

    A shift in BioScrip's (BIOS) strategy and the impact of implementing ASC 606 induce a Q2 earnings miss for the company. However, its progress with the new multi-faceted CORE plan is a positive.

      BioScrip (BIOS) Reports Q2 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      BioScrip (BIOS) delivered earnings and revenue surprises of -40.00% and 4.02%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        What's in the Cards for CVS Health (CVS) in Q2 Earnings?

        by Zacks Equity Research

        CVS Health (CVS) is optimistic about living up to its strong earnings surprise history year over year in Q2 as well, courtesy of gains from the Pharmacy Services segment.

          Can Overall Growth Drive ResMed's (RMD) Q4 Earnings?

          by Zacks Equity Research

          ResMed (RMD) is likely to keep its winning streak alive with a gain from strong performances on the domestic as well as global front in Q4.

            Can CAG Growth Continue to Aid IDEXX (IDXX) in Q2 Earnings?

            by Zacks Equity Research

            IDEXX (IDXX) is enhancing its commercial capabilities in the United States to maintain recurring revenue growth at CAG Diagnostics.

              Moving Average Crossover Alert: BioScrip (BIOS)

              by Zacks Equity Research

              BioScrip, Inc. (BIOS) is looking like an interesting pick from a technical perspective

                Here's Why You Should Invest in BioScrip (BIOS) Right Now

                by Zacks Equity Research

                We are upbeat about BioScrip's (BIOS) progress in the last reported quarter, courtesy of its multi-faceted CORE plan to improve financial position.

                  Nabaparna Bhattacharya headshot

                  Outpatient Market Gains on Social Awareness: 3 Stocks in Focus

                  by Nabaparna Bhattacharya

                  Here we discuss how Medical Outpatient and home healthcare continue to create opportunities for investors keen on parking their money in the healthcare space.

                    Why Is BioScrip (BIOS) Down 2% Since its Last Earnings Report?

                    by Zacks Equity Research

                    BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      BioScrip's Core Business Strong Despite Reimbursement Issues

                      by Zacks Equity Research

                      BioScrip (BIOS) consistently advances with its multi-faceted CORE plan to perk up the money matters. However, reimbursement cuts pertaining to 21st century Cures Act might hinder growth in 2018.

                        BioScrip (BIOS) Q1 Loss Wider Than Expected, Revenues Beat

                        by Zacks Equity Research

                        BioScrip's (BIOS) shift in strategy to raise core revenue mix hampers growth in Q1. Year-over-year rise in core product mix buoys optimism.

                          Why Is BioScrip (BIOS) Down 5.6% Since its Last Earnings Report?

                          by Zacks Equity Research

                          BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                            BioScrip's Dull 2017 Earnings a Woe, Core Business Robust

                            by Zacks Equity Research

                            BioScrip's (BIOS) strategy to specifically focus on core revenue mix hurts overall growth. However, the company's core infusion business remains strong.

                              Why BioScrip (BIOS) Could Be Positioned for a Slump

                              by Zacks Equity Research

                              BioScrip (BIOS) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

                                BioScrip (BIOS) Loss Widens in Q4, '18 View Holds Promise

                                by Zacks Equity Research

                                BioScrip's (BIOS) strategic shift toward raising its core revenue mix hampers growth. However, guidance for 2018 buoys optimism on the stock.

                                  BioScrip (BIOS) Q3 Loss Wider Than Expected, Revenues Miss

                                  by Zacks Equity Research

                                  BioSrip (BIOS) Q3 revenues affected by the company's shift in strategy to focus on core revenue mix, the impact of the Cures Act and contract modifications with UnitedHealthcare.

                                    BioScrip's Infusion Business Strong, Dull 2017 View a Drag (Revised)

                                    by Zacks Equity Research

                                    BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.

                                      BioScrip's Infusion Business Strong, Dull 2017 View a Drag

                                      by Zacks Equity Research

                                      BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.

                                        BioScrip (BIOS) Shows Strength: Stock Adds 6.6% in Session

                                        by Zacks Equity Research

                                        BioScrip, Inc. (BIOS) moved big last session, as its shares jumped almost 7% on the day.